Edition:
India

Nestle SA (NESN.S)

NESN.S on Virt-X Level 1

84.36CHF
16 Nov 2018
Change (% chg)

CHF0.38 (+0.45%)
Prev Close
CHF83.98
Open
CHF84.52
Day's High
CHF84.78
Day's Low
CHF83.72
Volume
6,255,065
Avg. Vol
4,909,663
52-wk High
CHF86.40
52-wk Low
CHF72.92

Chart for

About

Nestle S.A. is a nutrition, health and wellness company. The Company's segments are Zone Europe, Middle East and North Africa (EMENA); Zone Americas (AMS); Zone Asia, Oceania and sub-Saharan Africa (AOA); Nestle Waters; Nestle Nutrition, and Other Businesses. The Company operates in the United States, Greater China Region,... (more)

Overall

Beta: 0.77
Market Cap(Mil.): CHF257,998.09
Shares Outstanding(Mil.): 3,112.16
Dividend: 2.30
Yield (%): 2.77

Financials

  NESN.S Industry Sector
P/E (TTM): 27.68 22.49 40.49
EPS (TTM): 3.00 -- --
ROI: 10.06 12.20 61.41
ROE: 15.89 15.58 72.88

Nestle to shift Nespresso global HQ to Vevey to save money

ZURICH, Nov 16 Swiss food giant Nestle will relocate the headquarters of coffee business Nespresso in 2021 from Lausanne to the group's main campus in Vevey, 20 km (12 miles) away, to save money.

16 Nov 2018

UPDATE 1-Ackman's Pershing Square exits Mondelez in favor of other bets

NEW YORK, Nov 14 Billionaire investor William Ackman has turned his back on snack maker Mondelez International and put the money into potentially more lucrative bets, including global coffee company Starbucks and hotel operator Hilton Worldwide Holdings.

15 Nov 2018

Nestle's Purina PetCare mulls French plant sale, job cuts

PARIS, Nov 13 Nestle's Purina PetCare division could cut around 200 jobs in France through voluntary departures and it is also exploring options for its Quimperle plant in Brittany, including a sale, said a Nestle France spokesman.

13 Nov 2018

Nestle raises stake in food allergy drug developer Aimmune

The health science arm of Nestle SA will pay $98 million to raise its stake in Aimmune Therapeutics Inc, the drug developer said, as it prepares to submit a marketing application for its peanut allergy drug by the end of the year.

12 Nov 2018

UPDATE 2-Nestle raises stake in food allergy drug developer Aimmune

Nov 12 The health science arm of Nestle SA will pay $98 million to raise its stake in Aimmune Therapeutics Inc, the drug developer said, as it prepares to submit a marketing application for its peanut allergy drug by the end of the year.

12 Nov 2018

Nestle raises stake in food allergy drug developer Aimmune

Nov 12 The health science unit of Nestle SA would pay $98 million to increase its stake in Aimmune Therapeutics Inc, the drug developer for food allergies said on Monday.

12 Nov 2018

Swiss stocks - Factors to watch on Nov. 12

ZURICH/BERLIN, Nov 12 The Swiss blue-chip SMI was seen opening 0.4 percent higher at 9,111 points on Monday, according to premarket indications from bank Julius Baer .

12 Nov 2018

Illycaffe has no plans to sell minority stake: chairman

MILAN Italy's premium coffee maker illycaffe is not considering selling a minority stake in the family-owned company to financial investors, Chairman Andrea Illy told Reuters.

07 Nov 2018

Illycaffe has no plans to sell minority stake - chairman

MILAN, Nov 6 Italy's premium coffee maker illycaffe is not considering selling a minority stake in the family-owned company to financial investors, Chairman Andrea Illy told Reuters.

07 Nov 2018

Breakingviews - Private equity could scratch Nestlé skin-care itch

LONDON (Reuters Breakingviews) - Acne and other skin creams have had a spotty record at Nestlé, but a buyout group might do better. A unit at the world’s biggest food group that makes Botox rival Dysport may fetch at least 6 billion Swiss francs ($6 billion). Rival consumer groups may be put off by the business’s products and low margins, but they could appeal to a private equity firm. Facing pressure from activist Dan Loeb, Nestlé Chief Executive Mark Schneider announced a review of the divi

06 Nov 2018

Earnings vs. Estimates